問卷

TPIDB > Principal Investigator

Principal Investigator


Taipei Medical University Hospital (在職)

Division of Hematology & Oncology

Division of Urology

Division of Thoracic Medicine

Division of Urology

Digestive System Department

Taipei WanFang Hospital (Managed by Taipei Medical Univeristy) (在職)

Division of Urology

Division of Urology

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare (在職)

Division of Urology

Division of Hematology & Oncology

更新時間:2023-09-19

劉明哲LIU, MING-CHE
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 10 個月

篩選

List

46Cases

2025-09-01 - 2029-12-31

Not yet recruiting
A Phase 2, Randomized, Double-Blind, Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V540A in Healthy Females 16 to 26 Years of Age
  • Condition/Disease

    Healthy

  • Test Drug

    Injectables

Participate Sites
6Sites

Recruiting6Sites

2013-10-01 - 2014-03-01

Phase I

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2021-11-15 - 2022-12-15

Phase I

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2023-05-10 - 2025-04-30

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting6Sites

Terminated1Sites

2025-04-01 - 2026-04-01

Others

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2020-08-01 - 2023-08-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
19Sites

Not yet recruiting8Sites

Recruiting1Sites

Terminated10Sites

2016-08-01 - 2019-07-31

Phase I

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Not yet recruiting1Sites

2025-01-15 - 2027-12-31

Phase I/II

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2017-11-01 - 2022-12-31

Phase I/II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2022-07-01 - 2024-03-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

1 2 3 4 5